CODA Biotherapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched1 / 4
Sections to complete：02
01 / WHAT IT BUILT
What the company did
CODA researched chemogenetic gene therapies for difficult neurological conditions, including focal epilepsy.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Closure confirmed by investors
In March investors confirmed that the company had ceased operations but did not explain why.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Raised approximately $62.67 million in total.
- 02
Ceased operations in March 2023, as confirmed by Versant Ventures and MPM Capital; the website stayed online, but executives had been departing since fall 2022.
- 03
The reasons for the shutdown were never made public.
- 04
No audited loss figure was publicly disclosed.